The RosetteSepTM CTC Enrichment Cocktail—which targets CD2, CD16, CD19, CD38, CD45, CD66b, GYPA, and either CD36 or CD56 depending on tumour origin—is also currently on the market32, 33. The gene discussed is CEACAM8; the disease is neoplasm.